In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 7, 2015, Pages 1841-1850

  Silverman, Lisa ^a   Barenholz, Yechezkel ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Ammonia; Doxorubicin; Drug delivery; Glutaminolysis; Liposomal drug release; Liposomes

Indexed keywords

AMMONIA; DRUG DELIVERY; LIPOSOMES; MAMMALS; TARGETED DRUG DELIVERY; TUMORS;

DOXORUBICIN; DRUG RELEASE; ENHANCED PERMEABILITY AND RETENTION EFFECT; GLUTAMINOLYSIS; LIPOSOMAL DOXORUBICIN; MICROENVIRONMENTS; RELATED VARIABLES; THERAPEUTIC EFFICACY;

CONTROLLED DRUG DELIVERY;

AMMONIA; DOXORUBICIN; DRUG CARRIER; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; IN VITRO STUDY; MOUSE; NEOPLASM; NONHUMAN; PLASMA; STIMULUS RESPONSE; TUMOR CELL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CRYOELECTRON MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; HUMAN; NEOPLASMS; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

AMMONIA; ANIMALS; CELL LINE, TUMOR; CRYOELECTRON MICROSCOPY; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; HUMANS; MICE; NEOPLASMS; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942082397     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.06.007     Document Type: Article

References (37)

1. (R) - the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160(2):117-134.
2. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54(4):987-992.
3. Song G., Darr D.B., Santos C.M., Ross M., Valdivia A., Jordan J.L., et al. Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clin Cancer Res 2014, 20(23):6083-6095.
4. Chauhan V.P., Stylianopoulos T., Martin J.D., Popovic Z., Chen O., Kamoun W.S., et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012, 7(6):383-388.
5. Horowitz A.T., Barenholz Y., Gabizon A.A. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1992, 1109(2):203-209.
6. Huang S.K., Lee K.D., Hong K., Friend D.S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992, 52(19):5135-5143.
7. Jung S.H., Seong H., Cho S.H., Jeong K.S., Shin B.C. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm 2009, 382(1-2):254-261.
8. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994, 54(13):3352-3356.
9. Zamboni W.C., Gervais A.C., Egorin M.J., Schellens J.H., Zuhowski E.G., Pluim D., et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004, 53(4):329-336.
10. Peleg-Shulman T., Gibson D., Cohen R., Abra R., Barenholz Y. Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim Biophys Acta 2001, 1510(1-2):278-291.
11. Working P.K., Dayan A.D. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol 1996, 15(9):751-785.
12. Solomon R., Gabizon A.A. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma 2008, 8(1):21-32.
13. Gabizon A.A. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev 1995, 16(2):285-294.
14. Moreadith R.W., Lehninger A.L. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem 1984, 259(10):6215-6221.
15. Wang L., Zhou H., Wang Y., Cui G., Di L.J. CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4. Cell Death Dis 2015, 6:986-994. [e1620].
16. Koglin N., Mueller A., Berndt M., Schmitt-Willich H., Toschi L., Stephens A.W., et al. Specific PET imaging of xC- transporter activity using a (1)(8)F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism. Clin Cancer Res 2011, 17(18):6000-6011.
17. Baek S., Choi C.M., Ahn S.H., Lee J.W., Gong G., Ryu J.S., et al. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res 2012, 18(19):5427-5437.
18. Baek S., Mueller A., Lim Y.S., Lee H.C., Lee Y.J., Gong G., et al. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies. J Nucl Med 2013, 54(1):117-123.
19. Meister A. Metabolism of glutamine. Physiol Rev 1956, 36(1):103-127.
20. Gardner P.R., Raineri I., Epstein L.B., White C.W. Superoxide radical and iron modulate aconitase activity in mammalian cells. J Biol Chem 1995, 270(22):13399-13405.
21. de Gier J. Osmotic behaviour and permeability properties of liposomes. Chem Phys Lipids 1993, 64(1-3):187-196.
22. Deamer D.W., Bramhall J. Permeability of lipid bilayers to water and ionic solutes. Chem Phys Lipids 1986, 40(2-4):167-188.
23. Shibata H., Saito H., Yomota C., Kawanishi T. Ammonium ion level in serum affects doxorubicin release from liposomes. Pharmazie 2010, 65(4):251-253.
24. Eng C.H., Yu K., Lucas J., White E., Abraham R.T. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci Signal 2010, 3(119):ra31.
25. Cohen R., Steiner A., Kanaan H., Barenholz Y. Chemical and physical characterization of remotely loaded bupivacaine liposomes: comparison between large multivesicular vesicles and small unilamellar vesicles. J Mater Chem B 2013, 1:4619-4627.
26. Lasic D.D., Frederik P.M., Stuart M.C., Barenholz Y., McIntosh T.J. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 1992, 312(2-3):255-258.
27. Schroeder A., Honen R., Turjeman K., Gabizon A., Kost J., Barenholz Y. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release 2009, 137(1):63-68.
28. Hua S. Comparison of in vitro dialysis release methods of loperamide-encapsulated liposomal gel for topical drug delivery. Int J Nanomedicine 2014, 9:735-744.
29. Amselem S., Gabizon A., Barenholz Y. A large-scale method for the preparation of sterile and non-pyrogenic liposomal formulations of defined size distributions for clinical use. Liposome Technol 1993, 1:501-525.
30. Druckmann S., Gabizon A., Barenholz Y. Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. Biochim Biophys Acta 1989, 980(3):381-384.
31. Storm G., van Bloois L., Brouwer M., Crommelin D.J. The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation. Biochim Biophys Acta 1985, 818(3):343-351.
32. Barenholz Y. Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: from the bench to approved Doxil. Liposome technology 2007, vol. II:1-25. Informa Healthcare, New York, NY. 3rd ed.
33. Amselem S., Gabizon A., Barenholz Y. Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J Pharm Sci 1990, 79(12):1045-1052.
34. Needham D., Dewhirst M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001, 53(3):285-305.
35. Cohen R., Kanaan H., Grant G.J., Barenholz Y. Prolonged analgesia from Bupisome and Bupigel formulations: from design and fabrication to improved stability. J Control Release 2012, 160(2):346-352.
36. Andriyanov A.V., Koren E., Barenholz Y., Goldberg S.N. Therapeutic efficacy of combining PEGylated liposomal doxorubicin and radiofrequency (RF) ablation: comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes. PLoS One 2014, 9(5):e92555.
37. Ahmed M., Monsky W.E., Girnun G., Lukyanov A., D'Ippolito G., Kruskal J.B., et al. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 2003, 63(19):6327-6333.